Minerva Neurosciences (NERV) Enterprise Value (2013 - 2026)

Minerva Neurosciences has reported Enterprise Value for 14 years, with the latest figure at -$78.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 348.91% year-over-year to -$78.1 million; the trailing twelve-month figure through Mar 2026 stood at -$78.1 million (down 348.91% YoY), and the FY2025 full-year result was -$82.4 million, down 283.94% from the prior year.
• Enterprise Value for Q1 2026 stood at -$78.1 million, up from -$82.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$12.4 million in Q3 2025, with the low at -$82.4 million in Q4 2025.
• Historically, Enterprise Value has averaged -$39.7 million across 5 years, with a median of -$36.1 million in 2023.
• Annual changes were most pronounced in 2025 — Enterprise Value jumped 53.48% — and 2026, when it tumbled 348.91%.
• Minerva Neurosciences' Enterprise Value stood at -$34.7 million in 2022, then retreated by 18.34% to -$41.0 million in 2023, then jumped by 47.67% to -$21.5 million in 2024, then plunged by 283.94% to -$82.4 million in 2025, then climbed by 5.26% to -$78.1 million in 2026.
• The last three Enterprise Value figures came in at -$78.1 million (Q1 2026), -$82.4 million (Q4 2025), and -$12.4 million (Q3 2025), per Business Quant data.